Save items
Add to Favorites
loading
Similar articles in PubMed
Limiting "evergreening" for a better balance of drug innovation incentives.
[CMAJ. 2013]
Stanbrook MB.
CMAJ. 2013 Aug 6; 185(11):939. Epub 2013 Jul 22.
Drug patents: innovation v. accessibility.
[CMAJ. 2013]
Collier R.
CMAJ. 2013 Jun 11; 185(9):E379-80. Epub 2013 Apr 29.
A generic problem.
[Nat Clin Pract Gastroenterol H...]
Hanauer SB.
Nat Clin Pract Gastroenterol Hepatol. 2006 Dec; 3(12):649.
Licensing Compounds: lessons from ISTA Pharmaceuticals.
[Retina. 2005]
Anido V Jr.
Retina. 2005 Dec; 25(8 Suppl):S98.
Supplementary Protection Certificates for medicinal products: where are we now and what challenges lay ahead?
[Pharm Pat Anal. 2012]
Miles J.
Pharm Pat Anal. 2012 Jul; 1(3):275-84.
See reviews...
See all...
Cited by other articles in PMC
The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study
[Journal of Virus Eradication. ...]
Danta M, Ghinea N.
Journal of Virus Eradication. 2017 Apr 1; 3(2): 77-81
Nanodiamonds: The intersection of nanotechnology, drug development, and personalized medicine
[Science Advances. 2015]
Ho D, Wang CH, Chow EK.
Science Advances. 2015 Aug 21; 1(7): e1500439
Limiting “evergreening” for a better balance of drug innovation incentives
[CMAJ : Canadian Medical Associ...]
Stanbrook MB.
CMAJ : Canadian Medical Association Journal. 2013 Aug 6; 185(11): 939
See all...
Links
PubMed
PubMed
PubMed citations for these articles
Recent Activity
Clear
Turn Off
Turn On
Drug patents: the evergreening problem
Drug patents: the evergreening problem
CMAJ : Canadian Medical Association Journal. 2013 Jun 11; 185(9)E385
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on
See more...